MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

MDT

83.85

-0.46%↓

VEEV

224.68

-0.35%↓

A

105.25

-0.38%↓

WBA

11

+0.36%↑

CHE

545.53

-2.68%↓

Search

Johnson and Johnson

Open

SectorGezondheidszorg

153.45 -0.54

Overzicht

Wijziging aandelenprijs

24u

Huidig

Min

152.41

Max

155.08

Belangrijke statistieken

By Trading Economics

Inkomsten

3.4B

Verkoop

20M

23B

K/W

Sectorgemiddelde

17.455

57.333

EPS

2.77

Dividendrendement

3.3

Winstmarge

15.235

Werknemers

138,100

EBITDA

652M

5.9B

Aanbevelingen

By TipRanks

Aanbevelingen

Buy

12 Maanden Prognose

+9.18% upside

Dividenden

By Dow Jones

Dividendrendement

Sectorgemiddelde

3.30%

2.63%

Volgende Winsten

16 jul 2025

Volgende dividenddatum

10 jun 2025

Volgende Ex Dividend datum

27 mei 2025

Marktinformatie

By TradingEconomics

Marktkapitalisatie

11B

378B

Vorige openingsprijs

153.99

Vorige sluitingsprijs

153.45

Technische score

By Trading Central

Vertrouwen

Bullish Evidence

Johnson and Johnson Grafiek

Eerdere prestaties zijn geen betrouwbare indicator voor toekomstige resultaten.

Gerelateerd nieuws

15 apr 2025, 15:12 UTC

Winsten

J&J Boosts Outlook Despite Incoming Tariff Costs -- Update

15 apr 2025, 10:35 UTC

Top Nieuws
Winsten

J&J Increases Outlook After Beating 1Q Expectations

18 apr 2025, 11:00 UTC

Top Nieuws

Johnson & Johnson Pivots Its AI Strategy -- WSJ

17 apr 2025, 20:34 UTC

Winsten

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

17 apr 2025, 18:24 UTC

Winsten

UnitedHealth Woes Aren't Dragging Down the Entire Sector. Here's Why. -- Barrons.com

15 apr 2025, 19:06 UTC

Winsten

These Stocks Are Moving the Most Today: Bank of America, Citigroup, Netflix, Boeing, Tesla, HPE, Applied Digital, and More -- Barrons.com

15 apr 2025, 18:52 UTC

Marktinformatie
Winsten

J&J's 1Q Performance Signals Positive Outlook for MedTech Sector -- Market Talk

15 apr 2025, 14:54 UTC

Winsten

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 apr 2025, 13:19 UTC

Winsten
Acquisities, Fusies, Overnames

Why Johnson & Johnson Stock Is Down After Earnings Beat Expectations -- Barrons.com

15 apr 2025, 11:52 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 apr 2025, 11:14 UTC

Winsten

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Slips. -- Barrons.com

15 apr 2025, 10:51 UTC

Winsten

These Stocks Are Moving the Most Today: Boeing, Tesla, Bank of America, J&J, Netflix, Allegro MicroSystems, and More -- Barrons.com

15 apr 2025, 10:37 UTC

Top Nieuws
Winsten

Johnson & Johnson Tops Earnings Estimates and Boosts Outlook. The Stock Rises. -- Barrons.com

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson Now Sees 2025 Operational Sales of $91.6B-$92.4B Vs. Prior Outlook $90.9B-$91.7B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson Backs 2025 Adj EPS $10.50-Adj EPS $10.70 >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson Raises 2025 View To Sales $91B-$91.8B Vs Prior View $89.2B-$90B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson Now Sees 2025 Adjusted Operational EPS $10.50-$10.70 Vs Prior View $10.75-$10.95 >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson: Including Tariff Costs, Dilution From Intra-Cellular Therapies Buy and Updated Forex, Maintain FY Adj EPS Outlook of 6.2% Growth at Mid-Point >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson: Strong 1Q Operational Sales Growth Reinforces Our Confidence in 2025 Guidance >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q Sales $21.89B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson: Increasing FY25 Operational Sales Guidance to Reflect Addition of Caplyta Following Completion of Intra-Cellular Therapies Acquisition >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q Worldwide MedTech Sales $8.02B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q International Sales $9.59B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q Adj EPS $2.77 >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q Orthopaedics Sales $2.24B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson: MedTech 1Q Operational Sales Growth Driven Primarily by Abiomed and Wound Closure Products, Partially Offset by Spine, Sports & Other >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson Still Sees 2025 Adjusted Operational Sales Growth of 2.0%-3.0% >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson: Innovative Medicine 1Q Sales Growth Driven in Part by Higher Sales of Darzalex and Spravato, Partially Offset by Falling Sales of Stelara >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q U.S. Sales $12.31B >JNJ

15 apr 2025, 10:20 UTC

Winsten

Johnson & Johnson 1Q EPS $4.54 >JNJ

Peer Vergelijking

Prijswijziging

Johnson and Johnson Prognose

Koersdoel

By TipRanks

9.18% opwaarts potentieel

12 Maanden Prognose

Gemiddelde 169.15 USD  9.18%

Hoogste 185 USD

Laagste 159 USD

Gebaseerd op 14 Wall Street-analisten die 12-maands prijsdoelen bieden voor Johnson and Johnson - Dist. in de afgelopen 3 maanden.

Beoordelingsconsensus

By TipRanks

Buy

14 ratings

7

Buy

7

Hold

0

Sell

Technische score

By Trading Central

154.36 / 157.47Steun & Weerstand

Korte Termijn

Bullish Evidence

Gemiddeld Termijn

Bullish Evidence

Lange Termijn

Bearish Evidence

Financieel

Verkoop- en administratiekosten

Bedrijfskosten

Winst voor belastingen

Verkoop

Kosten van verkopen

Brutowinst op verkopen

Rente-uitgaven op schulden

EBITDA

Operationele winst

$

Over Johnson and Johnson

Johnson & Johnson, together with its subsidiaries, researches, develops, manufactures, and sells various products in the healthcare field worldwide. The company's Innovative Medicine segment offers products for various therapeutic areas, such as immunology, including rheumatoid arthritis, psoriatic arthritis, inflammatory bowel disease, and psoriasis; infectious diseases comprising HIV/AIDS; neuroscience, consisting of mood disorders, neurodegenerative disorders, and schizophrenia; oncology, such as prostate cancer, hematologic malignancies, lung cancer, and bladder cancer; cardiovascular and metabolism, including thrombosis, diabetes, and macular degeneration; and pulmonary hypertension comprising pulmonary arterial hypertension through retailers, wholesalers, distributors, hospitals, and healthcare professionals for prescription use. Its MedTech segment provides Interventional Solutions, including electrophysiology products to treat heart rhythm disorders; the heart recovery portfolio, which includes technologies to treat severe coronary artery disease requiring high-risk PCI or AMI cardiogenic shock; and neurovascular care that treats hemorrhagic and ischemic stroke. this segment also offers an orthopaedics portfolio that includes products and enabling technologies that support hips, knees, trauma, spine, sports, and other; surgery portfolios comprising advanced and general surgery technologies, as well as solutions for breast aesthetics, ear, nose, and throat procedures; contact lenses under the ACUVUE Brand; and TECNIS intraocular lenses for cataract surgery. It distributes its products to wholesalers, hospitals, and retailers, as well as physicians, nurses, hospitals, eye care professionals, and clinics. The company has a collaboration agreement with Stand Up To Cancer for research testing a combination of teclistamab and daratumumab to treat a rare disease AL amyloidosis. Johnson & Johnson was founded in 1886 and is based in New Brunswick, New Jersey.